CurrentBlue KCPolicy N/A

Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Defines Blue KC's reimbursement stance for serum and CSF biomarker testing used to diagnose multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and MOG-IgG-associated disease; applies to providers and facilities submitting claims to Blue KC commercial and Medicare Advantage lines of business.

Policy Summary

PayerBlue KC

PolicySerum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2025

Next Review DateJul 1, 202617d

Key ActionVerify member eligibility and benefits before ordering CSF or serum biomarker testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

07/01/2025policy effective date

001version number

Activepolicy status

Commercial & MAlines of business impacted

e.g., 83520, 83916

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and exclusions

Covered when ALL required conditions below are met; exclusions follow.

ALL of the following

ONE of
- Individual has atypical clinical, laboratory, or imaging features.
- Individual has an atypical clinically isolated syndrome (including but not limited to primary progressive MS or relapsing‑remitting course).
- Individual belongs to a population in which MS is less common (e.g., children, older individuals).
- Individual has insufficient clinical or imaging evidence for diagnosis.

ALL of the following

Individual has monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof.
Radiological or electrophysiological findings compatible with central nervous system (CNS) demyelination are present.
AND at least ONE of the following high‑risk features
- Belongs to a higher‑risk population (e.g., pediatric).
- Abnormal MRI with extensive optic nerve lesion, extensive spinal cord lesion or atrophy, or large confluent T2 brain lesions.
- Prominent papilledema, papillitis, or optic disc swelling during acute optic neuritis.

Exclusions

ELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG‑EM.
For diagnosis of MS, NMOSD, or MOG‑EM, all other CSF biomarker tests, including AQP4‑IgG or MOG‑IgG, are not reimbursed.
In all other situations not specified above, serum biomarker tests for multiple sclerosis are not reimbursed due to lack of sufficient published evidence of clinical benefit.

Administrative requirement: coverage determination is dependent on member eligibility and benefit limits at the time of request; providers should verify benefits and applicable coverage prior to testing.

Referenced procedure codes

Referenced procedure codesCPT | HCPCS | mixed

83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83916	Oligoclonal immune (oligoclonal bands)
84182	Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each
86051	Aquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA)
86052	Aquaporin-4 (neuromyelitis optica [NMO]) antibody; cell-based immunofluorescence assay (CBA), each
86053	Aquaporin-4 (neuromyelitis optica [NMO]) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each
86362	Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each
86363	Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure

1–10 of 11

1/2

Provider action and billing guidance

Prior Authorization

Verify member benefits before ordering

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Key definitions

Multiple sclerosis (MS)

DefinitionMultiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system characterized by multifocal areas of demyelination with loss of oligodendrocytes and astroglial scarring.

Typical symptomsMost commonly presents with sensory disturbances, followed by weakness and visual disturbances.

Clinical variabilityDisease course is highly variable with many atypical forms (e.g., ADEM, optic neuritis, transverse myelitis).

NMOSD

DefinitionNeuromyelitis optica spectrum disorders (NMOSD) are inflammatory CNS disorders characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord.

Relationship to MS